Form 4: REGENXBIO Director Karabelas Executes Stock Options and Sells Shares Under 10b5-1 Plan

Argeris N. Karabelas, a director at REGENXBIO Inc., exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 1, 2024, Argeris N. Karabelas, a director of REGENXBIO Inc., engaged in transactions involving the company's common stock.
• Karabelas exercised options to acquire 10,100 shares of common stock at prices of $3.76 and $12.74 per share.
• Concurrently, Karabelas sold 10,100 shares of common stock at prices ranging from $13.45 to $15.00 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Karabelas directly owns 11,286 shares of REGENXBIO Inc. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the director's outlook on the company.

Positives

• The use of a 10b5-1 trading plan suggests that the transactions were pre-planned and not based on insider information.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates